Agomab Therapeutics (AGMB) Common Equity (2024 - 2025)
Agomab Therapeutics (AGMB) posted quarterly Common Equity of $152.4 million for Q4 2025, down 24.18% year-over-year from $201.0 million in Q4 2024, and down 24.18% quarter-over-quarter from $201.0 million in Q4 2024.
Agomab Therapeutics (AGMB) Common Equity (2024 - 2025) Analysis & Trends
Agomab Therapeutics' Common Equity history runs 2 years deep, the most recent figure standing at $152.4 million for Q4 2025.
- In Q4 2025, Common Equity fell 24.18% year-over-year to $152.4 million; the TTM figure through Dec 2025 stood at $152.4 million (down 24.18% YoY), while the FY2025 annual figure was $152.4 million, down 25.15% from the prior year.
- Common Equity for Q4 2025 stood at $152.4 million, down from $201.0 million in the prior quarter.
- The five-year high for Common Equity was $201.0 million in Q4 2024, with the low at $152.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 9.79 Bn |
| 10 | Agomab Therapeutics | 7.20 Mn | -250.38 Mn | - | 308.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 152.38 Mn |
| Dec 31, 2024 | 200.98 Mn |